Retinoic acid-induced granulocytic differentiation of HL60 human promyelocytic leukemia cells is preceded by downregulation of autonomous generation of inositol lipid-derived second messengers.
Inositol phosphates (InsPs) and diacyglycerol (DAG) are second messengers derived via the breakdown of inositol phospholipids, and which play important signalling roles in the regulation of proliferation of some cell types. We have studied the operation of this pathway during the early stages of retionic acid (RA)-induced granulocytic differentiation of HL60 myeloid leukemia cells. The autonomous breakdown of inositol lipids that occurred in HL60 cells labeled with [3H] inositol was completely abolished following 48 hours of RA treatment. The rate of influx of 45Ca2+ was also significantly decreased at 48 hours, consistent with the role of inositol lipid-derived second messengers in regulating Ca2+ entry into cells. The downregulation of inositol lipid metabolism clearly preceded the onset of reduced proliferation induced by RA treatment, and was therefore not a consequence of decreased cell growth. The generation of InsPs in RA-treated cells was reactivated by the fluoroaluminate ion, a direct activator of guanine nucleotide-binding protein(s) (G proteins) that regulate the inositol lipid signalling pathway. Subtle alterations to a regulatory mechanism may therefore mediate the RA-induced downregulation of this pathway. The data are consistent with the hypothesis that the autonomous generation of inositol lipid-derived second messengers may contribute to the continuous proliferation of HL60 cells, and that the RA-induced downregulation of this pathway may, in turn, play a role in signalling the cessation of proliferation that preceedes granulocytic differentiation.
Porfiri
E
E
Department of Haematology, Royal Free Hospital School of Medicine, London, UK.
Hoffbrand
A V
AV
Wickremasinghe
R G
RG
D000535:Aluminum / Q000494:pharmacology; D002132:Calcium Radioisotopes / Q000378:metabolism; D002454:Cell Differentiation / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D004075:Diglycerides / Q000378:metabolism; D005461:Fluorine / Q000494:pharmacology; D006098:Granulocytes / Q000473:pathology*; D006801:Humans; D006868:Hydrolysis; D006918:Hydroxyurea / Q000494:pharmacology; D016130:Immunophenotyping; D007294:Inositol / Q000378:metabolism*; D007295:Inositol Phosphates / Q000378:metabolism; D007700:Kinetics; D015473:Leukemia, Promyelocytic, Acute / Q000378:metabolism / Q000473:pathology*; D050356:Lipid Metabolism; D043265:Phosphatidylinositol Diacylglycerol-Lyase; D010727:Phosphoric Diester Hydrolases / Q000378:metabolism; D015290:Second Messenger Systems; D014212:Tretinoin / Q000494:pharmacology*; D014407:Tumor Cells, Cultured
D002132:Calcium Radioisotopes; D004075:Diglycerides; D007295:Inositol Phosphates; C053629:fluoroaluminum; D005461:Fluorine; D007294:Inositol; D014212:Tretinoin; D000535:Aluminum; D010727:Phosphoric Diester Hydrolases; D043265:Phosphatidylinositol Diacylglycerol-Lyase; D006918:Hydroxyurea